Are TG2 inhibitors able to decrease gliadin-induced toxicity related to coeliac disease? – a proof-of-concept study
- T Rauhavirta (Speaker)
- R Kivistö (Speaker)
- Kaukinen, K. (Speaker)
- I Korponay-Szabo (Speaker)
- PT Männistö (Speaker)
- JA Garcia-Horsman (Speaker)
- A Mongeot (Speaker)
- R Collighan (Speaker)
- M Griffin (Speaker)
- Mäki, M. (Speaker)
- Lindfors, K. (Speaker)
Aktiviteetti: Konferenssiesitelmä